All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Martin Dreyling, Ludwig-Maximilians-Universität München, Munich, DE. We asked, What’s new in mantle cell lymphoma?
What’s new in mantle cell lymphoma?
In this video, Dreyling discusses the results of trials on rituximab maintenance and the standard approach in first relapse, such as ibrutinib, BTK inhibitors, and the combination of ibrutinib and bosutinib. To conclude, Dreyling outlines a comparison of chimeric antigen receptor (CAR) T-cell therapy and conventional therapies.
ASH 2019 | Practice-changing abstracts in lymphoma and CLL
The Lymphoma Hub has developed a downloadable resource, which provides an update on the practice-changing abstracts in lymphoma and CLL from ASH 2019 in preparation for ASH 2020.
Practice-changing abstracts in indolent lymphoma at EHA 2020
Interview with Martin Dreyling outlining the practice-changing abstracts in indolent lymphoma from EHA 2020.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox